Fibromyalgia is a chronic condition characterized by pain and tenderness. The primary goal of treatment is to reduce pain, and there are multiple well-established treatment options available, many of which are generic. Even though the majority of the diagnosed fibromyalgia population receives prescription drug treatment, most current therapies suffer from shortcomings in efficacy. The substantial percentage of patients with inadequate pain relief, the need for improved treatment of the secondary symptoms of fibromyalgia (e.g., anxiety, major depressive disorder, fatigue), and other areas with large unmet need (e.g., drugs that restore neuronal function)together pose ample commercial opportunity for new drugs that improve fibromyalgia treatment.


  •  What are surveyed rheumatologists’ opinions of the relative performance of select therapies, including Savella/Ixel/Milnaneurax (Allergan/Pierre Fabre/Neuraxpharm), Cymbalta/Xeristar (Eli Lilly/Boehringer Ingelheim), and Lyrica (Pfizer), on key efficacy, safety/tolerability, and convenience of administration attributes?
  • What are the top areas of unmet need and opportunity in fibromyalgia?
  • Based on the responses of surveyed physicians, what level of unmet need exists for key drug performance attributes?
  • What trade-offs in drug price and drug performance across key drug attributes are surveyed rheumatologists willing to make?

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 60 U.S. and 30 European rheumatologists fielded in January 2019.

Key companies: Allergan, Boehringer Ingelheim, Eli Lilly, Grünenthal, Janssen, Neuraxpharm, Pfizer, Pierre Fabre.

Key drugs: Duloxetine (Cymbalta/Xeristar, generics), gabapentin (Neurontin, generics), pregabalin (Lyrica, generics), milnacipran (Savella/Ixel, generics), tramadol (Ultram/Topalgic/Contramal/Tramal/Tramacet/Zydol, other brands, generics), amitriptyline, and cyclobenzaprine.


Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Table of contents

  • Detailed, Expanded Analysis | Fibromyalgia (US/EU)
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
      • Rationale for Drug Selection
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Key Findings: Stated vs. Derived Importance
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in Fibromyalgia and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the Fibromyalgia Market and Emerging Therapy Insights
        • Opportunity: A New Therapy Offering Greater Reduction in Pain Intensity
        • Opportunity: A New Therapy with an Improved Patient Responder Rate and Global Outcomes
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • Fibromyalgia Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2
    • Appendix
      • Bibliography

Author(s): Audreza Das, P.G. Dip

Audreza Das is a Senior Analyst in the CNS/Ophthalmology team at Decision Resources Group She has authored content across indications, including neuropathic pain, age-related macular degeneration, treatment-related depression, painful diabetic neuropathy, and migraine. Ms. Das has previously worked at Novo Nordisk, as a Market Analyst for European markets. Previous experience at a SME, included developing disease competitive landscapes, covering global conferences etc. Ms. Das received her degree in Biotechnology from Birla Institute of Technology, a deemed university and her Diploma in Cancer Immunology & Biotechnology from University of Nottingham.

Related Reports

Chronic Pain | Landscape & Forecast | Disease Landscape & Forecast

A crowded generics market makes gaining a strong foothold in the treatment of chronic pain challenging for branded agents. The treatment of chronic pain involves the use of drugs from several dru...

View Details

Chronic Pain | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis in Fibromyalgia (US)

Fibromyalgia is a complex disease that is difficult to treat because of patient heterogeneity, frequent comorbid conditions, and numerous symptoms, including pain, depression, fatigue, and sleep...

View Details

Chronic Pain | Current Treatment | Detailed, Expanded Analysis (US)

The treatment of chronic pain continues to provide unique challenges to physicians owing to the heterogeneity of pain pathophysiology within and across different chronic pain subtypes and the ab...

View Details

Chronic Pain | Special Topics | Special Topics: How will Anti-NGF Therapies Disrupt Existing Pain Treatment Algorithms? (US)

The most highly anticipated analgesic drugs in late-phase development belong to the anti-nerve growth factor (NGF) class: Pfizer / Eli Lilly’s tanez...

View Details